CD274 and neoplasm: Thus, inhibiting the PD-1/PD-L1 pathway reinstates the immune response against tumors and constitutes the rationale for using immune checkpoint blockade agents (ICIs) in tumor management; some examples of PD-1 or PD-L1 agents are: pembrolizumab, nivolumab, dostarlimab and cemiplimab or atezolizumab, avelumab and durvalumab, respectively.